. "Roho\u0148, Peter" . "[4D4898F645C0]" . . "263251" . "CZ - \u010Cesk\u00E1 republika" . . . "RIV/61989592:15110/10:10213467" . "RIV/61989592:15110/10:10213467!RIV11-MSM-15110___" . "1802-4475" . "immunomodulation; tyrosine kinase inhibitors; chronic myeloid leukemia"@en . . . . "S, Z(MSM6198959205)" . . "4"^^ . "3"^^ . . "Imunologick\u00FD profil pacientov s chronickou myel\u00F3zou lie\u010Den\u00FDch inhib\u00EDtormi tyrozinov\u00FDch kin\u00E1z - liter\u00E1rny prehlad" . "Imunologick\u00FD profil pacientov s chronickou myel\u00F3zou lie\u010Den\u00FDch inhib\u00EDtormi tyrozinov\u00FDch kin\u00E1z - liter\u00E1rny prehlad" . . . "Porkka, Kimmo" . . "chronick\u00E1 myelocytov\u00E1 leuk\u00E9mia (CML) je klonovou poruchou hemopoetickej kmenovej bunky s jej diferenci\u00E1ciou preva\u017Ene do myeloidn\u00E9ho radu. Inhib\u00EDtory tyrozinov\u00FDch kin\u00E1z (TKI) (imatinib, dasatinib, nilotinib) s\u00FA v s\u00FA\u010Dasnosti \u0161tandardom lie\u010Dby CML. Okrem inhib\u00EDcie BCR/ABL onkoprote\u00EDnu zasahuj\u00FA i tzv. off-target kin\u00E1zy (napr. c-KIT, SRC, TEC). Mnoh\u00E9 z nich zohr\u00E1vaj\u00FA dole\u017Eit\u00FA \u00FAlohu v imunitnej odpovedi. In vitro \u0161t\u00FAdie poukazuj\u00FA na imunosupres\u00EDvny \u00FA\u010Dinok TKI, velmi obmedzen\u00E9 s\u00FA v\u0161ak \u00FAdaje z in vivo anal\u00FDz. S\u00FAhrnom je mo\u017En\u00E9 kon\u0161tatova\u0165, \u017Ee pri lie\u010Dbe dasatinibom doch\u00E1dza u \u010Dasti pacientov k v\u00FDraznej aktiv\u00E1cii imunitnej odpovede, ktor\u00E1 vy\u017Eaduje intenz\u00EDvne sledovanie pacientov." . "1"^^ . "Immune profile of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors - literary review"@en . "Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoetic stem cell with myeloid differentiation predominantly. Tyrosine kinase inhibotors (TKI) (imatinib, dasatinib, nilotinib)are the current standard treatment in CML. In addition to the BCR-ABL oncoprotein, they also inhibit off-target kinases (e.g.c-KIT,SCR,TEC). Some of these kinases have physiological functions in immune responses. In vitro studies have implied immunosuppressive effects of TKI, but comprehensive data form in vivo analyses has been missing. In summary, in a distinct subgroup of dasatinib-treated patients, immune reactivity is significantly enhanced warrating careful follow-up."@en . . "4" . . "Onkologie" . "15110" . . . "Immune profile of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors - literary review"@en . "4" . "Mustjoki, Satu" .